Steven Park to Male
This is a "connection" page, showing publications Steven Park has written about Male.
Connection Strength
0.143
-
Moore DC, Soni AC, Hu B, Smith ET, Levine J, Moyo TK, Jacobs R, Ghosh N, Park SI. Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type. Br J Haematol. 2022 Feb; 196(4):e30-e33.
Score: 0.057
-
Hill H, Arnall J, Janes A, Hatley C, Swift K, Hargett C, Howell T, Griffin S, Larck C, Park S. A review of R-DHAP administration in the outpatient setting and a case of the alternative regimen R-DHAX given outpatient for refractory diffuse large B-cell lymphoma. J Oncol Pharm Pract. 2019 Dec; 25(8):2041-2044.
Score: 0.047
-
Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Epperla N, Mathews S, Burkart M, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Maddocks KJ, Badar T, Fenske TS, Hamadani M, Guo J, Malecek M, Kahl BS, Martin P, Blum KA, Flowers CR, Cohen JB. Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. Am J Hematol. 2021 Nov 01; 96(11):1374-1384.
Score: 0.014
-
Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, Barr PM, Winegarden JD, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, LeBlanc ML, Song JY, Fisher RI, Rimsza LM, Smith SM, Miller TP, Friedberg JW. Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. J Clin Oncol. 2020 Sep 10; 38(26):3003-3011.
Score: 0.013
-
Ghosh N, Sanikommu S, Robinson M, Trivedi J, Brown T, Bose R, Park SI, Avalos BR, Copelan EA, Jacobs R, Hu B. Curative potential of chemoimmunotherapy in diffuse large B cell lymphoma with hepatic and/or renal dysfunction. Br J Haematol. 2019 Aug; 186(4):e65-e67.
Score: 0.012